Use of oral cholera vaccine as a vaccine probe to determine the burden of culture-negative cholera.
Administration, Oral
Age Factors
Bangladesh
/ epidemiology
Cholera
/ diagnosis
Cholera Vaccines
/ administration & dosage
Clinical Trials, Phase III as Topic
Diarrhea
/ microbiology
Endemic Diseases
Feces
/ microbiology
Follow-Up Studies
Humans
Incidence
Microbiological Techniques
Randomized Controlled Trials as Topic
Seasons
Vaccines, Inactivated
/ administration & dosage
Vibrio cholerae O1
/ immunology
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
17
10
2018
accepted:
22
01
2019
entrez:
15
3
2019
pubmed:
15
3
2019
medline:
26
4
2019
Statut:
epublish
Résumé
Analyses of stool from patients with acute watery diarrhea (AWD) using sensitive molecular diagnostics have challenged whether fecal microbiological cultures have acceptably high sensitivity for cholera diagnosis. If true, these findings imply that current estimates of the global burden of cholera, which rely largely on culture-confirmation, may be underestimates. We conducted a vaccine probe study to evaluate this possibility, assessing whether an effective killed oral cholera vaccine (OCV) tested in a field trial in a cholera-endemic population conferred protection against cholera culture-negative AWD, with the assumption that if cultures are indeed insensitive, OCV protection in such cases should be detectable. We re-analysed the data of a Phase III individually-randomized placebo-controlled efficacy trial of killed OCVs conducted in Matlab, Bangladesh in 1985. We calculated the protective efficacy (PE) of a killed whole cell-only (WC-only) OCV against first-episodes of cholera culture-negative AWD during two years of post-dosing follow-up. In secondary analyses, we evaluated PE against cholera culture-negative AWD by age at vaccination, season of onset, and disease severity. In this trial 50,770 people received at least 2 complete doses of either WC-only OCV or placebo, and 791 first episodes of AWD were reported during the follow-up period, of which 365 were culture-positive for Vibrio cholerae O1. Of the 426 culture-negative AWD episodes, 215 occurred in the WC group and 211 occurred in the placebo group (adjusted PE = -1.7%; 95%CI -23.0 to 13.9%, p = 0.859). No measurable PE of OCV was observed against all or severe cholera culture-negative AWD when measured overall or by age and season subgroups. In this OCV probe study we detected no vaccine protection against AWD episodes for which fecal cultures were negative for Vibrio cholera O1. Results from this setting suggest that fecal cultures from patients with AWD were highly sensitive for cholera episodes that were etiologically attributable to this pathogen. Similar analyses of other OCV randomized controlled trials are recommended to corroborate these findings.
Identifiants
pubmed: 30870416
doi: 10.1371/journal.pntd.0007179
pii: PNTD-D-18-01531
pmc: PMC6417643
doi:
Substances chimiques
Cholera Vaccines
0
Vaccines, Inactivated
0
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007179Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Infect Dis. 2002 Jul 15;186(2):246-51
pubmed: 12134262
J Clin Microbiol. 2002 Sep;40(9):3296-9
pubmed: 12202569
Lancet. 1990 Feb 3;335(8684):270-3
pubmed: 1967730
J Clin Microbiol. 2010 Nov;48(11):3918-22
pubmed: 20739485
Lancet. 2013 Jul 20;382(9888):209-22
pubmed: 23680352
Lancet Infect Dis. 2013 Dec;13(12):1050-6
pubmed: 24140390
PLoS Negl Trop Dis. 2015 Jun 04;9(6):e0003832
pubmed: 26043000
N Engl J Med. 2016 May 5;374(18):1723-32
pubmed: 27144848
Lancet. 1986 Jul 19;2(8499):124-7
pubmed: 2873397
Lancet Infect Dis. 2018 Jun;18(6):666-674
pubmed: 29550406
J Infect Dis. 1988 Aug;158(2):372-7
pubmed: 3042876